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ABSTRACT 
 
BACKGROUND. Appropriate therapeutic management of iron deficiency anemia 
(IDA) is essential to prevent serious health risks and indiscriminate exposure to 
allogeneic blood transfusions. Iron therapy is administered intravenously in patients 
failing to respond to oral iron treatment or needing rapid iron repletion. Several 
parenteral iron carbohydrate complex formulations are now available, classified as 
stable, such as ferric carboxymaltose, or labile, such as sodium ferric gluconate, 
according to the release rate of iron, directly taken up by transferrin and other proteins. 
The first one preparations allow clinically well-tolerated administration of a single 
much higher dose of intravenous iron by more rapid infusion than the second one and 
various therapeutic areas can take advantages of their use, as appropriate therapy for 
IDA correction.  
 
STUDY DESIGN AND METHODS. In this retrospective study, we considered 346 
patients with IDA, eligible for the intravenous treatment. 222 patients (group A) 
received an average of three intravenous injections of ferric carboxymaltose (500 mg / 
visit), other 124 patients (group B) received an average of ten infusions of sodium 
ferric gluconate (62,5 mg / visit). Patients were assessed at first visit and at least after 
2, 5 and 7 weeks from the beginning of the treatment. The primary endpoint was the 
difference in the mean Hb, ferritin and transferrin saturation values detected 
throughout the whole observation period between the two treatment groups. Drug-
related adverse events and transfusion need were also evaluated.  
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RESULTS. Significantly lower baseline levels of Hb, ferritin and transferrin 
saturation (TSAT) were detected in group A, than in group B. Nevertheless, we found 
a faster and greater Hb, ferritin and TSAT increase with ferric carboxymaltose dosing 
regimen compared with sodium ferric gluconate. Throughout the whole observational 
period, group A showed a mean Hb level of 11,3 g/dL (95% CI 11,1 – 11,6), a mean 
ferritin level of 221,1 ng/mL (95% CI 184,4 – 257,7) and a mean TSAT of 20,7% 
(95% CI 18,9 – 22,5); group B showed a mean Hb level of 10,6 g/dL (95% CI 10,4 – 
10,8), a mean ferritin level of 85,4 ng/mL (95% CI 50,9 – 119,9) and a mean TSAT of 
14,1% (95% CI 11,8 – 16,4). After drug administration, statistical analysis showed a 
significant difference between the two groups in terms of mean Hb level (0,74 g/dL, 
95% CI 0,42 – 1,06, p<0,0001), mean ferritin level (135,7 ng/mL, 95% CI 85,3 – 
186,1, p<0,0001) and mean TSAT (6,6%, 95% CI 3,7 – 9,6, p<0,0001). The 
occurrence of intravenous iron-related adverse drug effects was very low and the 
difference among the two groups was not statistically significant (p=0,8). No serious 
adverse events were witnessed. Patients requiring transfusions after the beginning of 
the treatment decreased and were 1.4% in group A and 4.8% in group B (p=0,05). 
Even patients with baseline Hb ≤ 8 g/dL showed a greater increase in Hb 
concentration in group A compared to group B and a very low proportion of them 
needed transfusions.  
 
CONCLUSION. The results of this study suggest that ferric carboxymaltose can be 
used safely and more effectively than sodium ferric gluconate to rapidly improve and 
maintain raised Hb concentration and TSAT values after drug withdrawal in patients 
with iron-restricted erythropoiesis, avoiding their exposure to the potential risks of 
untreated anemia, unnecessary transfusions or both. 
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Background 
 
Several burgeoning data, including 
analysis of benchmark studies (1-2), 
suggest that there is a sleeping giant of 
undertreated patients with an unsafe 
condition of iron deficiency anemia (IDA) 
(3), for which intravenous iron 
supplementation should be warranted. 
Eligibility criteria for this therapy are: oral 
iron non-compliance / intolerance or 
ineffectiveness (4); severe IDA in 
pregnancy (beyond the first trimester) (5-
6) and postpartum (7-8); excessive 
bleeding (9-10); surgeries that decrease 
iron absorption (gastrectomy, duodenal 
bypass) (11); gastrointestinal tract 
disorders (active inflammatory bowel 
diseases; H. pylori colonization; impaired 
gastric acid secretion; coeliac disease) 
(12-16); erythropoietic-stimulating agents 
(ESA) therapy in chronic kidney disease 
(CKD) (17-18) and in cancer (19-21); 
CKD (irrespective of ESA) (22); genetic 
iron refractory IDA (IRIDA) (23); 
unaccepted blood transfusions for 
religious issues; a clinical need for a rapid 
iron supply, closely related to functional 
capacity, e.g. in the perioperative setting 
(24);  and acute event-related anaemia 
(AERA), in critical illness and tissue 
damage for the changes in iron 
metabolism induced by inflammatory 
effect (25). 
For all these clinical and surgical settings, 
different formulations of parenteral iron 
are now available, consisting of a mineral 
core of iron oxohydroxide, surrounded by 
a carbohydrate shell, that determine their 
pharmacological and biological 
differences. Following injection, stable 
complexes, with high molecular weight 
and structural homogeneity, such as ferric 
carboxymaltose (FCM) (molecular mass 
of 150,000 Daltons), slowly deliver iron to 
transferrin, only via macrophages 
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endocytosis and consequent controlled 
export (26). These preparations permit 
rapid and larger dose (up to 1000 mg / 
visit) infusions to be administered over 
short therapeutic course (27).  
In less stable preparations, such as sodium 
ferric gluconate (SFG) (molecular mass of 
37,500 Daltons), instead, iron is rapidly 
released from carbohydrate complex and 
only if they are given slowly in small 
doses (up to 62,5 - 125 mg / visit ) is the 
iron taken up, at first, via endocytosis by 
the macrophages and not directly by 
transferrin. If transferrin was quickly fully 
saturated, there would be large amounts of 
toxic non-transferrin bound iron in the 
serum, responsible for lipid peroxidation, 
reactive oxygen species formation (28) 
and, as a consequence, systemic side 
effects (29). The typical therapeutic 
course of such labile preparations requires 
up to 5 injections and so administration 
times are  markedly longer (30) than for 
stable complexes. 
The primary objective of this study was to 
evaluate the efficacy and safety of two 
different forms of parenteral iron, FCM 
compared with SFG, in patients with 
confirmed IDA of various etiologies. 
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Materials and methods 
 
Study overview 
In order to evaluate the effects of the two 
intravenous iron preparations, we 
performed a retrospective observational 
study, analyzing 346 patients 
consecutively admitted at 3 different 
centers for intravenous iron support 
between January 2009 and December 
2015. 
 
Study arms and outcome measures 
Subjects who received FCM, administered 
in an average of three infusions of 500 
mg, were allocated to the first arm (Group 
A); subjects who received SFG, 
administered in an average of ten 
infusions of 62,5 mg, were allocated to the 
second arm (Group B).   
All patients assigned to group A and B 
were clustered depending on various 
etiologies of IDA (pregnancy, postpartum, 
heavy uterine bleeding, gastrointestinal 
disorders, chronic heart failure, 
hematological disease, chronic disease or 
unexplained) and baseline hemoglobin 
(Hb) (≤8; 8,1-10; >10 g/dL). 
Laboratory tests, showing hematopoietic 
response and iron repletion, were obtained 
at the beginning of iron therapy and 2, 5 
and 7 weeks later.  
The primary endpoint was the difference 
in the mean Hb, ferritin and transferrin 
saturation (TSAT) values detected 
throughout the whole observation period 
from baseline to Day 49 between the two 
treatment groups.  
Other secondary endpoints included for 
each group, mean changes in Hb, ferritin 
and TSAT from baseline to Day 14, 35 
and 49; the difference in the percentage of 
patients achieving an increase in Hb value 
of at least 1 g/dL any time between 
baseline and Day 14; the highest Hb value 
observed any time from baseline to Day 
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35 and 49; mean change from baseline to 
the highest observed Hb value from 
baseline to Day 14 and 49, and proportion 
of patients requiring transfusion, in the 
cluster of patients with Hb≤8 g/dL, 
allocated to both treatment groups. 
Treatment-emergent adverse events and 
transfusion requirements in both groups, 
throughout the whole observation period 
of 7 weeks from the initiation of therapy, 
were also analyzed. 
 
Statistical analysis 
Variables with normal distribution are 
expressed as mean and SD, while 
categorical data as frequency and 
percentage. Between groups, comparisons 
of data were performed by t-test for 
unpaired data or the Mann-Whitney U-test 
for continuous variables, and by the chi-
square test for categorical variables. 
The independent relationship between the 
two forms of parenteral iron (FCM and 
SFG) and laboratory parameters over time 
(dependent variable) was investigated by a 
multiple linear mixed model and data 
were expressed as regression coefficient, 
95% confidence interval and p value. The 
significance level was set at p≤0,05.  
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Results 
 
Baseline data 
A total of 346 patients, affected by IDA, 
were allocated to the two different groups: 
222 supported with FCM to group A, and 
124 supported with SFG to group B. 
Baseline characteristics of these patients 
are listed in Table 1. Statistically 
significant differences were detected in 
laboratory data between the two groups, 
group A exhibiting lower mean values for 
Hb, ferritin and TSAT than group B. 
 
Table 1. Demographic characteristics* 
 Group A: FCM 
(n=222) 
Group B: SFG 
(n=124) 
p value 
Age (years) 58.4±17.7 55.8±18.4 0.29 
Sex 
Female 
Male 
 
171 (77.0) 
51 (23.0) 
 
98 (79.0) 
26 (21.0) 
0.67 
Etiology of IDA 
Pregnancy, post-partum, HUB 
Gastrointestinal disorders 
Chronic disease 
Chronic heart failure 
Hematological disease 
Unexplained 
 
69 (32.4) 
70 (32.9) 
35 (16.4) 
4 (1.9) 
6 (2.8) 
29 (13.1) 
 
23 (18.5) 
31 (25.0) 
22 (17.7) 
1 (0.8) 
10 (8.1) 
37 (29.8) 
<0.0001 
Baseline Hb (g/dL) 8.7±1.2 9.4±1.4 <0.0001 
Hb category (g/dL) 
≤8 
8.1-10 
>10 
 
66 (30.4) 
124 (57.1) 
27 (12.4) 
 
26 (21.0) 
55 (44.4) 
43 (34.7) 
<0.0001 
Baseline ferritin (ng/mL) 11.1±29.3 14.2±26.6 0.0003 
Baseline TSAT (%) 4.5±3.5 6.2±5.2 0.0006 
Previous ABT requirement  14 (6.3) 25 (20.2) <0.0001 
Previous iron therapy 96 (43.2) 56 (45.2) 0.7303 
Active bleeding 41 (18.6)  28 (22.6) 0.37 
*Data are expressed as means ± SD or as number (%) 
ABT=allogeneic blood transfusion; FCM=ferric carboxymaltose; HUB=heavy uterine bleeding; IDA=iron 
deficiency anemia; SFG=sodium ferric gluconate; TSAT=transferrin saturation. 
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Iron exposure 
Although the Ganzoni formula (31) is the 
best way to calculate patient’s total body 
iron deficit and to fully replete the iron 
stores, in clinical practice we utilized 
approved product labels (13), stating 
specific dosing regimens, to estimate 
intravenous iron needs. 
The mean cumulative dose of intravenous 
iron received from subjects was 
significantly higher in group A than group 
B: 1439,4 (±536,9) mg versus  632,4 
(±344) mg (p<0,0001); while the 
proportion of patients treated with iron 
therapy before baseline was similar 
between groups: 43,2% in group A and 
45,2% in group B (p=0,7303).   
 
Primary endpoint 
Group A was associated with a faster and 
greater increase in Hb, ferritin and TSAT 
level than group B, and the difference 
between the two groups reached the 
maximum from baseline to Day 28 
(Figure 1) for Hb level (2,47 g/dL; 95% 
CI 1,68-3,27); to Day 7 (Figure 2) for 
ferritin level (322,4 ng/ml; 95% CI 187,7-
457,2) and to Day 14 (Figure 3) for TSAT 
value (21,9%; 95% CI 13,5-30,4).  
Mean difference in mean Hb, ferritin and 
TSAT values detected throughout the 
whole observation period between Group 
A and Group B was statistically 
significant and respectively: 0,74 g/dL 
(95% CI 0,42 -1,06), p<0,0001; 135,7 
ng/mL (95% CI 85,3-186,1), p<0,0001; 
and 6,6% (95% CI 3,7 -9,6), p<0,0001; 
being mean Hb, ferritin and TSAT value 
observed in this period higher in group A 
than group B: respectively 11,3 g/dL 
(95% CI 11,1 - 11,6), 221,1 ng/ml (95% 
CI 184,4 - 257,7) and 20,7% (95% CI 18,9 
- 22,5) versus 10,6 g/dL (95% CI 10,4 - 
10,8), 85,4 ng/mL (95% CI 50,9 - 119,9) 
and 14,1% (95% CI 11,8 - 16,4). 
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Figure 1. Effects of ferric carboxymaltose (Group A, red line) and sodium ferric gluconate 
(Group B, blue line) on hemoglobin levels throughout the observation period of the study.  
 
 
Figure 2. Effects of ferric carboxymaltose (Group A, red line) and sodium ferric gluconate 
(Group B, blue line) on ferritin levels throughout the observation period of the study. 
Hemoglobin (g/dL) 
Ferritin (ng/mL) 
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Figure 3. Effects of ferric carboxymaltose (Group A, red line) and sodium ferric gluconate 
(Group B, blue line) on transferrin saturation throughout the observation period of the study. 
 
 
Secondary endpoints 
Mean increase in Hb, ferritin, and TSAT 
from baseline to highest value by Day 14 
was significantly greater in group A than 
group B: respectively, 2 (±1,2) g/dL 
versus 1,1(±0,9) g/dL, p=0,0057; 253,4 
(±165,5) ng/ml versus 49,3 (±46,8) ng/ml, 
p=0,019 and 22,8 (±20,6)% versus 2,5 
(±3,3)%, p=0,0398 (Table 2). 
Interestingly, while disappeared at Day 35 
(Table 3), such statistically significant 
differences between the FCM group and 
the SFG group, were confirmed at Day 49, 
when the average of Hb, ferritin and 
TSAT improvement from baseline was 
respectively 3,8 (±1,7) g/dL versus 1,2 
(±1,3) g/dL, p<0,0001; 124,7 (±124,4) 
ng/ml versus 55,8 (±83,5) ng/ml, 
Transferrin saturation (%) 
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p=0,0351 and 16,3 (±7,6) % versus 2,2 
(±1,3) %, p=0,0009 (Table 4). Of note, at 
the end of the observational period, in 
SFG group TSAT level returned close to 
baseline, while in FCM group TSAT 
remained stable, over 16%.  
 
 
Table 2. Mean increase from baseline ferritin, Hb and TSAT to Day 14* 
 Group A Group B p value 
Ferritin (ng/mL) 253.4 ± 165.5 49.3 ± 46.8 0.019 
Hb (g/dL) 2.0 ± 1.2 1.1 ± 0.9 0.0057 
TSAT (%) 22.8 ± 20.6 2.5 ± 3.3 0.0398 
*Data are expressed as mean ± SD. Hb=haemoglobin; TSAT=transferrin saturation. 
 
Table 3. Mean increase from baseline ferritin, Hb and TSAT to Day 35* 
 Group A Group B p value 
Ferritin (ng/mL) 115.2 ± 97.9 49.5 ± 45.4 0.4939 
Hb (g/dL) 2.2 ± 2.3 1.8 ± 1.8 0.5269 
TSAT (%) 14.9 ± 9.5 11.9 ± 11.8 1 
*Data are expressed as mean ± SD. Hb=haemoglobin; TSAT=transferrin saturation. 
 
Table 4. Mean increase from baseline ferritin, Hb and TSAT to Day 49* 
 Group A Group B p value 
Ferritin (ng/mL) 124.7 ± 124.4 55.8 ± 83.5 0.0351 
Hb (g/dL) 3.8 ± 1.7 1.2 ± 1.3 < 0.0001 
TSAT (%) 16.3 ± 7.6 2.2 ± 1.3 0.0009 
*Data are expressed as mean ± SD. Hb=hemoglobin; TSAT=transferrin saturation. 
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The proportion of patients who achieved 
an increase in Hb level of at least 1 g/dL 
from baseline to Day 14 was significantly 
greater in group A than group B: 82,1% 
(95% CI 66,9 - 91,2) versus 45% (95% CI 
25,3 - 66,4), p=0,005.  
Likewise, the highest Hb value reached 
from baseline to Day 35 was significantly 
greater in group A than group B: 11 (±1,4) 
g/dL versus 10,6 (±1,4) g/dL, p= 0,015; 
such as the highest Hb value recorded 
from baseline to Day 49: 11,5 (±1,7) g/dL 
versus 10,9 (±1,3) g/dL, p=0,0006.  
In the subgroup of 92 patients with Hb 
level ≤8 g/dL (66 supported with FCM 
and 26 with SFG), we found a mean 
increase in Hb from baseline to Day 14 
that did not significantly differ, between 
group A and group B: 2,4 (±1,4) g/dL 
versus 1,4  (±0,8) g/dL, p=0,1837. The 
difference between the groups became 
statistically significant to Day 49, when 
mean increase in Hb level from baseline 
was 4,6 (±2,1) g/dL in the FCM group 
versus 2,7 (±0,8) g/dL in the SFG group 
(p=0,0041). 
In both subgroups of severely anemic 
subjects, we found a very low proportion 
of patients requiring transfusion after the 
beginning of parenteral iron therapy: 
3,03% in group A and 3,85% in group B 
(p=1). Fisher exact test was used for 
statistical analysis and the lack of a 
statistically significant difference between 
the two subgroups may be due to sample 
size that didn’t provide the power to 
detect a treatment difference. 
 
Adverse events and transfusion need 
There weren’t any serious adverse events 
in both groups and there wasn’t a 
statistically significant difference in the 
proportion of patients who experienced a 
possibly drug-related side effect: 5.4 % in 
group A versus 7.2 % in group B, 
p=0,0821. The most common adverse 
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events in the group A were mild 
hypersensitivity reactions, reversible even 
without therapy (2,3%) and dizziness 
(1,8%); conversely, the most common 
adverse events in the group B were 
nausea/vomit (1,6%), and epigastric pain 
(1,6%) (Table 5). 
 
Table 5. Adverse events* 
Adverse event Group A Group B 
Headache 0 (0.0) 1 (0.8) 
Dizziness 4 (1.8) 0 (0.0) 
Nausea/vomit 1 (0.5) 2 (1.6) 
Epigastric pain 0 (0.0) 2 (1.6) 
Back pain 0 (0.0) 1 (0.8) 
Mild hypersensitivity reactions 5 (2.3) 1 (0.8) 
Abdominal pain 0 (0.0) 1 (0.8) 
Dysphagia 1 (0.5) 0 (0.0) 
  *Data are expressed as number (%). 
 
The proportion of patients receiving 
transfusions before starting intravenous 
therapy was significantly higher in group 
B than group A (20,2% versus 6,3%, 
p<0,0001), such us after the beginning of 
treatment, when subjects requiring 
transfusion decreased and were 4,8% in 
group B versus 1,4% in group A (p=0,05) 
(Table 6), with 19 packed red blood cells 
(PRBC) units transfused in group B versus 
6 in group A. 
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Table 6. Transfusion need before and after intravenous iron injection* 
 Group A Group B P value 
Patients transfused before iron injection 14 (6.3) 25 (20.2) < 0.0001 
Patients transfused after iron injection 3 (1.4) 6 (4.8) 0.05 
*Data are expressed as number (%). 
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Discussion 
 
Our aim was to compare the effects of two 
forms of parenteral iron in patients with 
iron-restricted erythropoiesis. 
We analyzed patients with every type of 
iron deficiency (ID): absolute ID, 
functional ID (for following treatment 
with ESA), and ID associated with 
chronic disease (ACD/IDA).  
The ACD/IDA diagnosis wasn’t always 
straightforward, because of the lack of a 
widely available assay for determination 
of hepcidin-25 isoform (32), that, best of 
all, reflects iron need for erythropoiesis 
(33-34), without being an invasive 
method, like bone marrow aspiration 
stained with Prussian blue. 
Subjects labeled “unexplained”, 
unresponsive to oral iron therapy, mostly 
“baby boomers” with a negative 
gastrointestinal workup, represented a 
sharp proportion in both groups of our 
study and, after hematologic evaluation, 
were examined by serology  for H. pylori 
IgG, celiac disease, serum gastrin and 
antiparietal/intrinsic factor antibodies, 
even if their noncompliance, for frequent 
side effects and multiple daily doses 
concerning to oral iron therapy (35), often 
affected this refractoriness.  
In clinical practice, FCM stands out by the 
rate at which a maximum single dose can 
be infused safely, with fewer visits need, 
facilitating a rapid haematological 
response and iron replacement. 
Our findings show that this newer 
formulation produces significantly greater 
and faster increases in Hb, ferritin and 
TSAT levels than SFG, maintaining raised 
their values even after drug withdrawal 
(Figure 1, 2, 3).  
The low rate of adverse events of FCM 
was comparable to that of SFG, and 
supports the evidence that these 
preparations are safe (36), provided that 
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published European Medicines Agency’s 
Committee for Medicinal Products for 
Human Use advice (37) is followed. 
Infusion reactions (itching, flushing, 
dizziness, nausea), described in our 
patients and common with newer 
formulations (38), usually did not require 
any therapy and resolved without residua 
(39-40). Misinterpretation of the clinical 
nature of these mild reactions, deemed as 
serious adverse events and treated over-
aggressively, often with vasopressors and 
antihistamines, fueled the historical 
perception of peril attributed to the 
intravenous iron, that novel 
comprehensive reviews reply (22,36).  
Furthermore, in terms of safety, our 
experience confirmes that intravenous iron 
administration, by readily increasing 
hematopoietic response rate, decreases 
allogeneic blood transfusion need, being 
proportion of subjects requiring 
transfusion, even among severely anemic 
patients, lower in the FCM group than 
SFG group.   
Properly administered, FCM, with an 
estimated incidence of serious adverse 
events of <1:200.000, is much safer than 
allogeneic blood transfusion (41), 
associated with events responsible for 
major morbidity in 1:21.413 components 
issued (according to the Serious Hazards 
of Transfusion 2012 data) (42). 
In respect to infectious complications, 
transfusion of even a single PRBC unit 
may limit the immune response, induce 
inflammatory mediators (43)  and delivers 
on average 200 mg of Heme Fe, which 
has growth-promoting effect on 
microorganisms (44), in contrast to 
commercial intravenous iron complex, 
that has been demonstrated in various 
surgical settings not to increase infection 
rate (45-46).  
Additionally, FCM, although its higher 
acquisition cost than SFG, may be 
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considered a less expensive alternative 
(47-48). Factors to be taken into 
consideration include the lower frequency 
of infusion need and the resulting 
advantages both for the patient, with 
lower working days lost, and for the 
health system, with lower overhead costs: 
both direct (e.g., medical and nursing 
staff, infusion material, laboratory tests , 
with materials needed for sampling) and 
indirect (e.g., utilities, property and 
nonprofessional personnel), being the 
second ones the highest proportion of the 
total cost of the treatment.  
Nowadays, the central purpose of health 
care organizations, including transfusion 
medicine services, is to maintain the 
greatest benefit for patients at lower 
overall cost, and for patients with iron 
deficiency, without hemodynamic 
instability, it means to actively treat 
underlying disease and replete iron stores 
for erythropoiesis, with oral and/or 
intravenous iron supplementation, without 
adopting transfusion as front line therapy 
if clinically unnecessary (49).  
In conclusion, our data suggest that, in 
appropriately selected individuals needing 
replenishment of iron stores, 
administration of FCM is an accurate 
approach, as safe and more effective than 
SFG, rapidly increasing medullary 
response and iron store, maintaining 
raised Hb and TSAT values even after 
drug withdrawal and decreasing 
transfusion need, with costs and 
complications related. 
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